Clinical Trial Update: A Study to Evaluate SHR-1139 Injection in Patients With Pyoderma Gangrenosum [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating SHR-1139 injection in patients with pyoderma gangrenosum. The study status is NOT_YET_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pyoderma Gangrenosum

Drugs mentioned

• SHR-1139

Snippet

Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | Conditions: Pyoderma Gangrenosum | Phase 2 | Status: NOT_YET_RECRUITING